{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:35:18Z","timestamp":1787841318731,"version":"build-2784847793"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,5]],"date-time":"2018-07-05T00:00:00Z","timestamp":1530748800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Thrombocytopenia is a relatively common complication following allogeneic hematopoietic stem cell transplantation and is associated with increased bleeding, transfusion requirements, chronic graft-versus-host disease, and all-cause mortality. There are currently no approved treatments outside of supportive transfusions. We report on the outcomes of five patients at our institution who received romiplostim for either primary engraftment failure or secondary failure of platelet recovery following stem cell transplantation. In total, four out of the five patients demonstrated a response to romiplostim, which was defined as seven consecutive days of platelet count &gt;50 \u00d7 10\n                      <jats:sup>9<\/jats:sup>\n                      \/L with transfusion independence, with two ongoing responses (&gt;365 days each) at the conclusion of the study period. Responses to romiplostim were sustained in the absence of significant bone marrow disease, which was found to contribute to recurrent thrombocytopenia. Additionally, romiplostim was well-tolerated overall; one patient developed minimal fibrotic changes on bone marrow biopsy postromiplostim. Although these results are promising, data from randomized clinical trials are needed to fully understand the role of romiplostim after stem cell transplantation.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1016\/j.hemonc.2018.07.002","type":"journal-article","created":{"date-parts":[[2018,7,17]],"date-time":"2018-07-17T14:42:29Z","timestamp":1531838549000},"page":"171-174","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Romiplostim for thrombocytopenia following allogeneic stem cell transplantation"],"prefix":"10.4103","volume":"13","author":[{"given":"Guido","family":"Lancman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Coltoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-9-20241211","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1634\/theoncologist.1-6-371","article-title":"The problem of thrombocytopenia after hematopoietic stem cell transplantation","volume":"1","author":"Nash","year":"1996","journal-title":"Oncologist"},{"key":"R2-9-20241211","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1053\/bbmt.2001.v7.pm11302549","article-title":"Secondary failure of platelet recovery after hematopoietic stem cell transplantation","volume":"7","author":"Bruno","year":"2001","journal-title":"Biol Blood Marrow Transplant"},{"key":"R3-9-20241211","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/sj.bmt.1704330","article-title":"Prognostic importance of the platelet count 100 days post allogeneic bone marrow transplant","volume":"33","author":"Bolwell","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"R4-9-20241211","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0140-6736(08)60203-2","article-title":"Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial","volume":"371","author":"Kuter","year":"2008","journal-title":"Lancet"},{"key":"R5-9-20241211","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1200\/JCO.2009.24.7999","article-title":"Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia","volume":"28","author":"Kantarjian","year":"2009","journal-title":"J Clin Oncol"},{"key":"R6-9-20241211","first-page":"260","article-title":"Romiplostim for delayed platelet recovery and secondary thrombocytopenia following allogeneic stem cell transplantation","volume":"3","author":"Poon","year":"2013","journal-title":"Am J Blood Res"},{"key":"R7-9-20241211","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1038\/bmt.2011.179","article-title":"Romiplostim. AMG531, Nplate for secondary failure of platelet recovery after allo-SCT","volume":"46","author":"Calmettes","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"R8-9-20241211","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1177\/1078155215612240","article-title":"Evaluation of romiplostim for the treatment of secondary failure of platelet recovery among allogeneic hematopoietic stem cell transplant patients","volume":"23","author":"Hartranft","year":"2017","journal-title":"J Oncol Pharm Pract"},{"key":"R9-9-20241211","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1182\/blood.V128.22.65.65","article-title":"Romiplostim in patients undergoing allogeneic stem cell transplantation: results of a phase I\/II multicenter trial","volume":"128","author":"de Latour","year":"2016","journal-title":"Blood"},{"key":"R10-9-20241211","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1016\/S2352-3026(18)30016-4","article-title":"Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial","volume":"5","author":"Kantarjian","year":"2018","journal-title":"Lancet Haematol"},{"key":"R11-9-20241211","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0925-5710(96)00487-2","article-title":"Serum thrombopoietin level after allogeneic bone marrow transplantation: possible correlations with platelet recovery, acute graft-versus-host disease and hepatic veno-occlusive disease. Nagoya Bone Marrow Transplantation Group","volume":"64","author":"Hamaguchi","year":"1996","journal-title":"Int J Hematol"},{"key":"R12-9-20241211","first-page":"1065","article-title":"Eltrombopag for refractory thrombocytopenia in patients with allogeneic hematopoietic stem cell transplantation","volume":"37","author":"Ma","year":"2016","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"R13-9-20241211","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1182\/blood.V120.21.4651.4651","article-title":"Switching from romiplostim to eltrombopag or vice versa for immune thrombocytopenia: efficacy and safety in 46 patients","volume":"120","author":"Khellaf","year":"2012","journal-title":"Blood"},{"key":"R14-9-20241211","doi-asserted-by":"crossref","first-page":"E40","DOI":"10.1002\/ajh.23900","article-title":"Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia","volume":"90","author":"Gonz\u00e1lez-L\u00f3pez","year":"2015","journal-title":"Am J Hematol"}],"container-title":["Hematology\/Oncology and Stem Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658387618300657?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658387618300657?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ovid.com\/10.1016\/j.hemonc.2018.07.002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:49:30Z","timestamp":1787838570000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1016\/j.hemonc.2018.07.002"}},"subtitle":["A case series"],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":14,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1016\/j.hemonc.2018.07.002","relation":{},"ISSN":["1658-3876"],"issn-type":[{"value":"1658-3876","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]}}}